Sarepta Therapeutics Inc (SRPT)
Financial leverage ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 3,963,170 | 3,599,930 | 3,424,260 | 3,224,380 | 3,264,580 | 3,109,710 | 3,125,890 | 3,059,790 | 3,128,370 | 3,156,150 | 2,996,850 | 3,056,150 | 3,147,970 | 2,662,220 | 2,759,070 | 2,765,230 | 2,984,720 | 2,780,660 | 2,883,040 | 2,947,390 |
| Total stockholders’ equity | US$ in thousands | 1,527,740 | 1,221,070 | 1,077,070 | 961,192 | 859,337 | 764,357 | 741,411 | 712,749 | 384,950 | 430,840 | 726,457 | 856,886 | 928,009 | 469,528 | 485,108 | 535,445 | 761,759 | 892,047 | 1,042,870 | 1,144,830 |
| Financial leverage ratio | 2.59 | 2.95 | 3.18 | 3.35 | 3.80 | 4.07 | 4.22 | 4.29 | 8.13 | 7.33 | 4.13 | 3.57 | 3.39 | 5.67 | 5.69 | 5.16 | 3.92 | 3.12 | 2.76 | 2.57 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $3,963,170K ÷ $1,527,740K
= 2.59
The financial leverage ratio of Sarepta Therapeutics Inc has shown fluctuation over the period from March 31, 2020, to December 31, 2024. The ratio started at 2.57 in March 2020, increased steadily to reach a peak of 8.13 by December 31, 2022, before decreasing to 2.59 by December 31, 2024.
The upward trend in the financial leverage ratio from March 2020 to December 2022 indicates that the company increased its reliance on debt to finance its operations and growth. This could be a cause for concern as higher leverage levels generally imply higher financial risk due to increased interest payments and potential financial distress.
However, the subsequent decrease in the ratio from 8.13 in December 2022 to 2.59 in December 2024 may signal a shift towards a more conservative capital structure, potentially reducing the company's financial risk and improving its financial stability.
Overall, the fluctuation in Sarepta Therapeutics Inc's financial leverage ratio suggests varying degrees of financial risk and capital structure adjustments during the period under review, reflecting the company's financing strategy and financial management decisions.
Peer comparison
Dec 31, 2024